Planned ATAK™ Clinical Programs
Myeloid Therapeutics is planning multiple phase I clinical trials leveraging our proprietary ATAK™ platform to address the critical global viral crisis' in addition to important cancer indications
ATAK™ Cell Vaccine Studies
MT-201 ATAK™ Vaccine for glioblastoma. A collaboration between Duke and Myeloid Therapeutics.
Planned Phase 1: Single arm open-label ascending dose trial of myeloid vaccine in subjects with glioblastoma.
MT-202 COVID-19 ATAK™ Vaccine for Long-Term T cell Immunity A collaboration between Duke and Myeloid Therapeutics & MaxCyte.
Planned Phase 1: Single arm open-label ascending dose trial of COVID-19 myeloid vaccine in healthy subjects.
(T cell lymphomas)
MT-101 CD5-ATAK™ cell therapy for subjects with CD5 expressing T cell lymphomas
Planned Phase 1: Single arm open label ascending dose trial in subjects with CD5 expressing peripheral T cell lymphoma.
(HER2 expressing Gastric Cancer)
Cell Therapy for subjects with HER2 expressing malignancies.
Planned Phase 1: Single arm open-label ascending dose trial in subjects with HER2+ expressing gastric/GEJ malignancies.